Ann Arbor’s Freestride nails down start-up funding

Most drugs being developed in the Ann Arbor area have human implications. Freestride Therapeutics is turning that idea on its head by repurposing a human drug stalled in development for animals.

The downtown Ann Arbor-based company began developing the drug for veterinary therapies in August. The drug relieves and even prevents shin pain for racing horses. It even has implications for companion animals, like dogs and cats, suffering from arthritis.

"It's painful for the horses," says David Olson, CEO of Freestride Therapeutics. "There is no FDA-approved treatment for preventing this."

Olson and his two partners, Michael Long and Noura Bashshar, plan to continue clinical trails for the next couple of years before receiving for FDA approval. The start-up also received a few thousand dollars from the Michigan Pre-Seed Capital Fund to continue its research.

Source: David Olson, CEO of Freestride Therapeutics
Writer: Jon Zemke

Ann Arbor’s Freestride nails down start-up funding

Related Tags

Recommended Content

Across Our Network